Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA proof-of-concept study (NCT05560646) was evaluating Organon’s therapy, ...

Bio-Thera Solutions has announced the early termination of its pivotal Phase II/III clinical trial of BAT4406F for NMOSD.

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.